Endometriosis is the single biggest leading-indicator story of the week. The condition tops the Emerging Demand Index at 1.36, powered by an 80% week-over-week jump in Wikipedia pageviews and 7 new recruiting clinical trials registered in the last 30 days. For Ob-Gyn and women's health operators, that's a consumer-attention spike confirmed by a research-side supply response — the cleanest two-source signal we've seen in weeks.

Emerging Demand — What to Watch

  • Endometriosis (EDI 1.36) — Wikipedia pageviews +80% WoW plus 7 new recruiting trials in 30 days. Consumer curiosity and research pipeline moving together; specialties to staff are Ob-Gyn and Women's Health.
  • Ozempic (EDI 0.86) — Wikipedia pageviews +60% WoW and a Breakout-tier rising query ("olivia wilde ozempic"). This is celebrity-driven attention, not a regulatory event — expect a short half-life but a sharp lead-gen window.
  • Zepbound (EDI 0.67) — Wikipedia pageviews +50% WoW with no offsetting FDA or trial activity. Pure consumer pull; the GLP-1 category as a whole remains the dominant search-driven demand engine.
  • Insomnia (EDI 0.63) — Wikipedia pageviews +49% WoW. No news or regulatory catalyst we can identify, which usually means an organic seasonal lift in sleep medicine demand.
  • Knee pain (EDI 0.63) — Wikipedia pageviews +49% WoW. Consistent with the late-spring orthopedic ramp as outdoor activity resumes; orthopedic and sports-med clinics should be pacing ad spend up now.
  • Worth flagging just outside the top 5: depression (EDI 0.62) is the only signal with three-source confirmation — Wikipedia +45% and 19 new recruiting trials in 30 days — making it the most structurally durable item on the board for psychiatry operators.

Search Intent

Google Trends shows no nationally rising conditions this week, which means the EDI signals above are running ahead of coincident search demand rather than confirmed by it — exactly what a leading indicator should look like. On the falling side, "annual physical" searches are down 25% (4-week avg of 23 vs prior 31) and "atrial fibrillation" is down 19%. The annual-physical drop is seasonal — the post-New Year wellness wave has fully unwound — and primary care marketers should rebudget away from that keyword cluster through summer.

Structural Markets

With no new BRFSS state-level deltas this cycle, the structural read is unchanged: GLP-1-eligible obesity prevalence remains the largest untapped capacity gap in the South and Appalachia, and operators in those markets should treat the Ozempic and Zepbound EDI signals as compounding on an already-elevated baseline.

The Bottom Line

If you run an Ob-Gyn or women's health line, this is the week to pull forward endometriosis-focused content and paid search — the Wikipedia-plus-trials combination is the strongest leading signal on the board. GLP-1 operators should ride the celebrity-driven Ozempic bump with short-flight creative rather than evergreen spend, and orthopedic clinics should confirm knee-pain capacity is staffed for a late-May ramp.